Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine aimed at training immune system to fight advanced breast cancer enters first human tests

NCT ID NCT06746688

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: ExpreS2ion Biotechnologies Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new vaccine called ES2B-C001, with or without an immune booster (adjuvant), in 40 people with HER2-positive metastatic breast cancer who have already tried other treatments. The vaccine is designed to help the body's immune system recognize and attack cancer cells. The main goal is to check safety and find the best dose, while also looking at whether the vaccine triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ES2B-C001 (a vaccine) with or without an adjuvant (ISA 51 VD)
What this could lead to
If it works, this could point toward a new vaccine-based treatment for HER2-positive metastatic breast cancer that helps the immune system fight the cancer.
What could go wrong
This is a very early, small phase 1 trial focused on safety, not effectiveness. The vaccine may not trigger a strong enough immune response or may cause side effects. It is only for patients who have already tried other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST CANCER, METASTATIC

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Medical University Of Vienna

    RECRUITING

    Vienna, 1090, Austria

  • Medical University of Graz

    RECRUITING

    Graz, Austria

  • Ordensklinikum Linz GmbH Barmherzige Schwestern

    RECRUITING

    Linz, 4010, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.